SABCS

Adjuvant Carboplatin and PARP Inhibitor Combination Trials in TNBC

Rebecca Shatsky, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

4 Significant Trials for HER2+ Breast Cancer at SABCS 2025

Harold Burstein, MD, PhD, Rohit Gosain, MD, Rahul Gosain, MD, MBA

HR+ Metastatic Breast Cancer Updates from SABCS 2025

Hope Rugo, MD, FASCO, Rahul Gosain, MD, MBA, Rohit Gosain, MD

From ADCs to Oral SERDs: Practice-Changing Insights from SABCS 2025

Zunairah Shah, MD

Impact of ADCs in Early TNBC Treatment

Mariam Haji Ahmad, MBBCh, Alexis Levee, MD

ADCs in TNBC: Current Data and Unanswered Questions

Pietro De Placido, MD, Dionisia Quiroga, DO, PhD

SABCS 2025 Updates on Inavolisib and Giredestrant in Breast Cancer

Tyler Kristoff, MD, Sarah Premji, MD

Key HR+, Early Breast Cancer Abstracts From SABCS 2025

Laura Huppert, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

The Evolving Role of T-DXd Across HER2+ Breast Cancer

Yash Agrawal, MD, Stephanie Graff, MD, FACP, FASCO

Patient Advocacy Brings Breast Cancer Vaccine to Phase 1 Trial

Judy Fitzgerald, Karissa Britten, MD

NATALEE 5-Year IDFS Data at SABCS 2025

Matthew Kurian, MD, Jasmin Hundal, MD

Anti-TROP-2 ADCs in PD-L1-Negative TNBC

Alexis Levee, MD, Paolo Tarantino, MD

Emerging Roles of Biomarkers in HER2-Positive Breast Cancer

Yash Agrawal, MD, Madison Canning, MD

Updates in HER2-Positive Breast Cancer From SABCS 2025

Vaishali Deenadayalan, MD

SABCS 2025: Expert Perspective on CDK4/6 Inhibitor Use in Metastatic Hormone Receptor-Positive Breast Cancer

Matthew Kurian, MD, Elia Segui Solis, MD

De-escalation and Sequencing Strategies Shape HER2-Positive Breast Cancer Care at SABCS 2025

Nerea Lopetegui-Lia, MD, Ya Haddy Sallah, MD, MPH

Shifting Treatment Paradigms in Hormone Receptor–Positive Breast Cancer

Jasmin Hundal, MD

SABCS 2025: HER2CLIMB-05 and DESTINY Trials Point to More Individualized Care in HER2-Positive Breast Cancer

Nerea Lopetegui-Lia, MD, Susan Dent, BSc, MD

SABCS 2025: Clarifying Where Sacituzumab Govitecan Fits in the Breast Cancer Treatment Landscape

Erika Hamilton, MD, FASCO, Dionisia Quiroga, DO, PhD

NATALEE and Other Updates for HR+ Early Breast Cancer at SABCS 2025

Komal Jhaveri, MD, FACP, Matthew Kurian, MD

Evolving Treatment Paradigms in Advanced Breast Cancer: Key Trial Updates From SABCS 2025

Karissa Britten, MD, Vaishali Deenadayalan, MD

Key Insights From the NATALEE Trial

Karissa Britten, MD, Matthew Kurian, MD

Evolving Approaches to Early-Stage and Metastatic TNBC

Briana To, DO, PhD

SABCS 2025: Evolving Role of CDK4/6 Inhibitors and SERDs in ER-Positive Breast Cancer

Kevin Kalinsky, MD, MS, FASCO, Sarah Premji, MD

Advances in Managing CNS Metastases in Breast Cancer: SABCS 2024 Insights

Hetal Mistry, MD